(Q38040710)

27 August 2017

title

Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses (English)

1 reference

27 August 2017

4

Alicja Węgrzyn

1 reference

27 August 2017

Magdalena Gabig-Cimińska

series ordinal

3

object named as

Magdalena Gabig-Cimińska

1 reference

27 August 2017

5

Grzegorz Węgrzyn

1 reference

Joanna Jakóbkiewicz-Banecka

27 August 2017

series ordinal

2

object named as

Joanna Jakóbkiewicz-Banecka

1 reference

27 August 2017

Zyta Banecka-Majkutewicz

series ordinal

1

object named as

Zyta Banecka-Majkutewicz

1 reference

27 August 2017

publication date

5 September 2012

1 reference

Archivum Immunologiae et Therapiae Experimentalis

27 August 2017

published in

1 reference

27 August 2017

volume

60

1 reference

27 August 2017

issue

6

1 reference

27 August 2017

page(s)

461-468

1 reference

Therapies for neurological disease in the mucopolysaccharidoses.

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Gene therapy: some history, applications, problems, and prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Genistein supplementation in patients affected by Sanfilippo disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

METABOLISM OF ACID MUCOPOLYSACCHARIDES.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Impairment of glycosaminoglycan synthesis in mucopolysaccharidosis type IIIA cells by using siRNA: a potential therapeutic approach for Sanfilippo disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Heparanase: busy at the cell surface

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Substrate deprivation therapy: a new hope for patients suffering from neuronopathic forms of inherited lysosomal storage diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Substrate reduction therapies for mucopolysaccharidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Gene silencing of EXTL2 and EXTL3 as a substrate deprivation therapy for heparan sulphate storing mucopolysaccharidoses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Effects of flavonoids on glycosaminoglycan synthesis: implications for substrate reduction therapy in Sanfilippo disease and other mucopolysaccharidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Allogeneic stem cell transplantation does not improve neurological deficits in mucopolysaccharidosis type IIIA mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Substrate reduction therapy with miglustat for type 1 Gaucher disease: a retrospective analysis from a single institution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Intrathecal administration of recombinant human N-acetylgalactosamine 4-sulfatase to a MPS VI patient with pachymeningitis cervicalis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Genistin-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: An open-label, pilot study in 10 pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Different amounts of isoflavones in various commercially available soy extracts in the light of gene expression-targeted isoflavone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Transplant outcomes in mucopolysaccharidoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Clarifying lysosomal storage diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Gene expression-targeted isoflavone therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Guidance on the use of miglustat for treating patients with type 1 Gaucher disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

Enzyme replacement therapy with idursulfase in patients with mucopolysaccharidosis type II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00005-012-0195-9

10.1007/S00005-012-0195-9

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

27 August 2017

1044529479

0 references

1 reference